| Objective: To observe the effects of combine treatment of ziyedan capsules and tenofovir alafenamide fumarate tablets on liver function, liver fibrosis and serum macrophage colony-stimulating factor (M-CSF), connective tissue growth factor (CTGF) and chitinase 3-like protein 1 (CHI3L1) in patients with chronic hepatitis B (CHB). Methods:138 CHB patients admitted to our hospital from October 2019 to October 2022 were selected. The grouping method was random number table method, patients were divided into control group (treated with tenofovir alafenamide fumarate tablets) and study group (combined treatment with ziyedan capsules on the basis of control group), 69 cases in each group. The efficacy, liver function indexes, serum M-CSF, CTGF, CHI3L1 levels, hepatitis B e antigen (HBeAg) negative rate, hepatitis B virus DNA quantitative detection (HBV-DNA) negative rate, liver fibrosis indexes and incidence of adverse reactions were compared between two groups. Results:The total clinical effective rate in study group was higher than that in control group (P<0.05). Alanine aminotransferase (ALT), M-CSF, aspartate aminotransferase (AST), type III procollagen (PC-III), CTGF, hyaluronic acid (HA), total bilirubin (TBiL), type IV collagen (IV-C), CHI3L1 and laminin (LN) in study group were lower than those in control group after treatment, while HBeAg negative conversion rate and HBV-DNA negative conversion rate were higher than those in control group (P<0.05). There was no difference in the incidence of adverse reactions between two groups (P>0.05).Conclusion:The combination of ziyedan capsules and tenofovir alafenamide fumarate tablets in the treatment of CHB patients, which can effectively improve the liver function, the degree of liver fibrosis, the levels of serum M-CSF, CTGF and CHI3L1, and increase the negative conversion rate of HBeAg and HBV-DNA. |
